10-Q Filing

MERCK & CO., INC. CIK: 310158 Q2 2022

Filing Information

Form Type	10-Q
Accession Number	`0000310158-22-000030`
Period End Date	20220630
Filing Date	20220805
Fiscal Year	2022
Fiscal Period	Q2
XBRL Instance	mrk-20220630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 80 Cash Flow Statement 80 Comprehensive Income 24

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$62.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$82.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.19B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.76B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.19B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.10B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.68B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.80B	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	-	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$453.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $82 in 2022 and $62 in 2021)	`AccountsReceivableNetCurrent`	$9.64B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $82 in 2022 and $62 in 2021)	`AccountsReceivableNetCurrent`	$9.23B	USD	Point-in-time
Inventories (excludes inventories of $2,764 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7)	`InventoryNet`	$5.54B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $2,764 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7)	`InventoryNet`	$5.95B	USD	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$6.99B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$6.81B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$32.12B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$30.27B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$370.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$238.00M	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,798 in 2022 and $18,192 in 2021	`PropertyPlantAndEquipmentNet`	$19.28B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,798 in 2022 and $18,192 in 2021	`PropertyPlantAndEquipmentNet`	$20.06B	USD	Point-in-time
Goodwill	`Goodwill`	$21.26B	USD	Point-in-time
Goodwill	`Goodwill`	$21.21B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$22.50B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$22.93B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$11.58B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$10.97B	USD	Point-in-time
Total Assets	`Assets`	$107.09B	USD	Point-in-time
Total Assets	`Assets`	$105.69B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.41B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.98B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.61B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.48B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$13.50B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$13.86B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.22B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.44B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.77B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.77B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$23.17B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$23.87B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$30.69B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$28.68B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$3.44B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$2.97B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.95B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$9.43B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.24B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.12B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.70B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$58.44B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.33B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.43B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.29B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$100.01B	USD	Point-in-time
Less treasury stock, at cost: 1,043,894,068 shares in 2022 and 1,049,499,023 shares in 2021	`TreasuryStockCommonValue`	$56.77B	USD	Point-in-time
Less treasury stock, at cost: 1,043,894,068 shares in 2022 and 1,049,499,023 shares in 2021	`TreasuryStockCommonValue`	$57.11B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$43.24B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$38.18B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$73.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$75.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.04B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$33.39B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.95B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.32B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$105.69B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$107.09B	USD	Point-in-time

Income Statement 80 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$14.59B	USD	1 Quarter
Sales	`Revenues`	$22.03B	USD	2 Qtrs
Sales	`Revenues`	$30.49B	USD	2 Qtrs
Sales	`Revenues`	$11.40B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$6.30B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$3.10B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.22B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$9.60B	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.83B	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.28B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.51B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.47B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.80B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$6.73B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$5.37B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.32B	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$194.00M	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$380.00M	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$82.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$142.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-1.15B	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$558.00M	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$103.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-438.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.11B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$9.69B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$17.32B	USD	2 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$21.15B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$1.72B	USD	1 Quarter
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.70B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$9.35B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.49B	USD	1 Quarter
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$741.00M	USD	2 Qtrs
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$538.00M	USD	1 Quarter
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$1.09B	USD	2 Qtrs
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$503.00M	USD	1 Quarter
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.96B	USD	2 Qtrs
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.95B	USD	1 Quarter
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$8.26B	USD	2 Qtrs
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$1.21B	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$1.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$5.00M	USD	2 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$2.00M	USD	2 Qtrs
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$3.96B	USD	2 Qtrs
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$8.25B	USD	2 Qtrs
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$1.21B	USD	1 Quarter
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$3.94B	USD	1 Quarter
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$332.00M	USD	1 Quarter
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$766.00M	USD	2 Qtrs
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	1 Quarter
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	-	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$8.25B	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.94B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.72B	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.54B	USD	1 Quarter
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$1.56	USD	2 Qtrs
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$3.26	USD	2 Qtrs
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$0.48	USD	1 Quarter
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerBasicShare`	$1.56	USD	1 Quarter
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.13	USD	1 Quarter
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	1 Quarter
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	-	USD	2 Qtrs
Income from Discontinued Operations (in dollars per share)	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.30	USD	2 Qtrs
Net Income (in dollars per share)	`EarningsPerShareBasic`	$3.26	USD	2 Qtrs
Net Income (in dollars per share)	`EarningsPerShareBasic`	$1.56	USD	1 Quarter
Net Income (in dollars per share)	`EarningsPerShareBasic`	$1.87	USD	2 Qtrs
Net Income (in dollars per share)	`EarningsPerShareBasic`	$0.61	USD	1 Quarter
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$1.55	USD	1 Quarter
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$1.56	USD	2 Qtrs
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$3.25	USD	2 Qtrs
Income from Continuing Operations (in dollars per share)	`IncomeLossFromContinuingOperationsPerDilutedShare`	$0.48	USD	1 Quarter
Income from Discontinued Operations (in dollars per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	-	USD	1 Quarter
Income from Discontinued Operations (in dollars per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.30	USD	2 Qtrs
Income from Discontinued Operations (in dollars per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	-	USD	2 Qtrs
Income from Discontinued Operations (in dollars per share)	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.13	USD	1 Quarter
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$1.55	USD	1 Quarter
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$1.86	USD	2 Qtrs
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$0.61	USD	1 Quarter
Net Income (in dollars per share)	`EarningsPerShareDiluted`	$3.25	USD	2 Qtrs

Cash Flow Statement 80 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$78.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$71.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$103.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$55.00M	USD	Point-in-time
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.96B	USD	2 Qtrs
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.95B	USD	1 Quarter
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$8.26B	USD	2 Qtrs
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$1.21B	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$1.16B	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$871.00M	USD	2 Qtrs
Depreciation	`Depreciation`	$749.00M	USD	2 Qtrs
Depreciation	`Depreciation`	$895.00M	USD	2 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$23.00M	USD	2 Qtrs
Loss (income) from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$280.00M	USD	1 Quarter
Loss (income) from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-991.00M	USD	2 Qtrs
Loss (income) from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$854.00M	USD	2 Qtrs
Loss (income) from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-284.00M	USD	1 Quarter
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.56B	USD	2 Qtrs
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-600.00M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$29.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$257.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$243.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-328.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$-776.00M	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.65B	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.70B	USD	2 Qtrs
Net Cash Provided by Operating Activities of Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$3.23B	USD	2 Qtrs
Net Cash Provided by Operating Activities of Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$9.06B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.07B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.11B	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$1.00M	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$705.00M	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$374.00M	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$386.00M	USD	2 Qtrs
Acquisition of Pandion Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of Pandion Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.55B	USD	2 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$90.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-16.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-194.00M	USD	2 Qtrs
Net Cash Used in Investing Activities of Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-3.31B	USD	2 Qtrs
Net Cash Used in Investing Activities of Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-2.25B	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	-	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-3.98B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.15B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.25B	USD	2 Qtrs
Distribution from Organon & Co.	`DisposalGroupInclDiscontinuedOperationsDistributionReceived`	-	USD	2 Qtrs
Distribution from Organon & Co.	`DisposalGroupInclDiscontinuedOperationsDistributionReceived`	$9.00B	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$239.00M	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.32B	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.52B	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$51.00M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$109.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-194.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-207.00M	USD	2 Qtrs
Net Cash (Used in) Provided by Financing Activities of Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-4.86B	USD	2 Qtrs
Net Cash (Used in) Provided by Financing Activities of Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$164.00M	USD	2 Qtrs
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$1.05B	USD	2 Qtrs
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$-134.00M	USD	2 Qtrs
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	$-504.00M	USD	2 Qtrs
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	-	USD	2 Qtrs
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	$413.00M	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-19.00M	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-364.00M	USD	2 Qtrs
Net Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$477.00M	USD	2 Qtrs
Net Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.59B	USD	2 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.75B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.63B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78 and $55 at June 30, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.17B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78 and $55 at June 30, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78 and $55 at June 30, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.75B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78 and $55 at June 30, 2022 and 2021, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.63B	USD	Point-in-time

Comprehensive Income 24 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$8.25B	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.94B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.72B	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.54B	USD	1 Quarter
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$183.00M	USD	1 Quarter
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$240.00M	USD	2 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$246.00M	USD	2 Qtrs
Net unrealized gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$10.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-1.40B	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-1.48B	USD	2 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-278.00M	USD	2 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-246.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$132.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-422.00M	USD	2 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-167.00M	USD	2 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-387.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$42.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.56B	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$102.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.54B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$8.36B	USD	2 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.99B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$6.28B	USD	2 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.09B	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.